Drugs / NNC0650-0013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06284798 | Jan → Jul 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0650-0013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06284798 ↗ |
| Route | Intravenous | “NNC0650-0013 will be administered subcutaneously or intravenously.” NCT06284798 ↗ |
| Route | Subcutaneous | “NNC0650-0013 will be administered subcutaneously or intravenously.” NCT06284798 ↗ |